Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412585 | PMC |
| http://dx.doi.org/10.1136/esmoopen-2020-000769 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
School of Pharmacy, Chapman University, Irvine, CA, USA.
Background: Although novel treatments for Alzheimer's disease (AD) have begun to show modest therapeutic effects, agents that target hallmark AD pathology and offer neuroprotection are desired. Erythropoietin (EPO) is a glycoprotein hormone with neuroprotective effects but is faced with challenges including limited brain uptake and increased hematopoietic side effects with long-term dosing. Therefore, EPO has been modified and bound to a chimeric transferrin receptor monoclonal antibody (cTfRMAb); the latter shuttles EPO past the blood-brain barrier (BBB) into brain parenchyma and reduces its plasma exposure and potential for side effects.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
North Bristol NHS Trust, Bristol, United Kingdom.
Background: Poor sleep is associated with neurodegenerative diseases underlying dementia and mild cognitive impairment (MCI), including Alzheimer's disease (AD) and Lewy body disease (LBD). Performing assessments within clinical or laboratory settings may influence validity, however feasibility of home sleep and memory assessments in this population is currently undetermined. This study aimed to identify whether remote home-based sleep and memory research including wearable technology was feasible in older adults with MCI and dementia.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Background: The earliest cognitive manifestations of asymptomatic and prodromal familial frontotemporal dementia (f-FTD) mutation carriers are still being characterized. Patients with symptomatic FTD are known to be error prone, particularly on tasks of executive function, but little is known about the frequency or predictive utility of these errors in the earliest stages of f-FTD. The current study compared error rates on executive functioning tasks in controls and asymptomatic and prodromal mutation carriers and investigated whether errors predict worsening clinical status as follow up.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
Odessa National Maritime University, Odessa, Ukraine.
Background: Alzheimer's disease can cause sleep disturbances in humans, which can worsen other symptoms of the disease.
Method: In our study, we examined the sleep patterns of 23 patients with Alzheimer's disease, aged 65-74 years (20 women and 3 men), over 4 months. All patients reported experiencing poor sleep, including difficulty sleeping in the ward, frequent awakenings during the night, early morning awakenings, and daytime sleepiness.
Technology and Dementia Preconference.
Alzheimers Dement
December 2024
Yuan Ze University, Taoyuan CIty, Taoyuan, Taiwan.
Background: Effect of dynamic lighting on sleep were studied since 1980's. Traditional light sources were used due to lack of advancement in technology and also researchers assumed illuminance as cause of melatonin suppression. This led researchers to use high illuminance to suppress melatonin at day time.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!